133 related articles for article (PubMed ID: 38223616)
1. Antibody response to pneumococcal conjugate vaccine 10 among Nigerian children under 5 years.
Udah CA; Iregbu FU; Ekanem EE
Afr Health Sci; 2023 Jun; 23(2):186-192. PubMed ID: 38223616
[TBL] [Abstract][Full Text] [Related]
2. Kinetics of pneumococcal antibodies among HIV-exposed, uninfected infants in Botswana.
Uffman EA; Li SH; Chen JL; Allen N; Boiditswe S; Fouda GG; Hurst JH; Patel MZ; Steenhoff AP; Cunningham CK; Qin E; Davenport CA; Kelly MS
Vaccine; 2022 Aug; 40(33):4764-4771. PubMed ID: 35773120
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.
Clarke E; Bashorun A; Adigweme I; Badjie Hydara M; Umesi A; Futa A; Ochoge M; Obayemi D; Edem B; Saidy-Jah E; Onwuchekwa C; Dhere R; Sethna V; Kampmann B; Goldblatt D; Taylor D; Andi-Lolo I; Hosken N; Antony K; Innis BL; Alderson MR; Lamola S
Lancet Infect Dis; 2021 Jun; 21(6):834-846. PubMed ID: 33516293
[TBL] [Abstract][Full Text] [Related]
4. The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children.
Thanee C; Pancharoen C; Likitnukul S; Luangwedchakarn V; Umrod P; Phasomsap C; Apornpong T; Chuanchareon T; Butterworth O; Puthanakit T
Vaccine; 2011 Aug; 29(35):5886-91. PubMed ID: 21729732
[TBL] [Abstract][Full Text] [Related]
5. Dose-specific Effectiveness of 7- and 13-Valent Pneumococcal Conjugate Vaccines Against Vaccine-serotype Streptococcus pneumoniae Colonization in Children.
Lewnard JA; Givon-Lavi N; Dagan R
Clin Infect Dis; 2020 Nov; 71(8):e289-e300. PubMed ID: 31784753
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and Reactogenicity of 13-Valent Pneumococcal Conjugate Vaccine Among Infants, Toddlers, and Children in Western Burkina Faso: Results From a Clinical Trial of Alternative Immunization Schedules.
Moïsi JC; Yaro S; Kroman SS; Gouem C; Bayane D; Ganama S; Meda B; Nacro B; Njanpop-Lafourcade BM; Ouangraoua S; Ouedraogo I; Sakande S; Sawadogo F; Zida S; Ouedraogo JB; Gessner BD
J Pediatric Infect Dis Soc; 2019 Nov; 8(5):422-432. PubMed ID: 30299491
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of a 10-valent pneumococcal conjugate vaccine administered as a 2 + 1 schedule to healthy infants in The Gambia: a single-centre, double-blind, active-controlled, randomised, phase 3 trial.
Adigweme I; Futa A; Saidy-Jah E; Edem B; Akpalu E; Dibbasey T; Sethna V; Dhere R; Kampmann B; Bengt C; Sirr J; Hosken N; Goldblatt D; Antony K; Alderson MR; Lamola S; Clarke E
Lancet Infect Dis; 2023 May; 23(5):609-620. PubMed ID: 36638819
[TBL] [Abstract][Full Text] [Related]
8. Antibody titers eight months after three doses of a five-valent pneumococcal conjugate vaccine in HIV and non-HIV-infected children less than two years of age.
King JC; Vink PE; Chang I; Kimura A; Parks M; Smilie M; Lichenstein R; Farley JJ
Vaccine; 1998 Feb; 16(4):361-5. PubMed ID: 9607056
[TBL] [Abstract][Full Text] [Related]
9. Pneumonia hospitalizations and mortality in children 3 - 24-month-old in Nigeria from 2013 to 2020: Impact of pneumococcal conjugate vaccine ten valent (PHiD-CV-10).
Iliya J; Shatima DR; Tagbo BN; Ayede AI; Fagbohun AO; Rasaq A; Nalban S; Elon IW; Mohammed-Nafiu R; Ahmed P; Oyewole OB; Bakare AA; Yusuf BO; Akinrinoye OO; Ogala WN; Falade AG
Hum Vaccin Immunother; 2023 Dec; 19(1):2162289. PubMed ID: 36597576
[TBL] [Abstract][Full Text] [Related]
10. Epidemiological and molecular characterization of Streptococcus pneumoniae carriage strains in pre-school children in Arkhangelsk, northern European Russia, prior to the introduction of conjugate pneumococcal vaccines.
Vorobieva S Jensen V; Furberg AS; Slotved HC; Bazhukova T; Haldorsen B; Caugant DA; Sundsfjord A; Valentiner-Branth P; Simonsen GS
BMC Infect Dis; 2020 Apr; 20(1):279. PubMed ID: 32293324
[TBL] [Abstract][Full Text] [Related]
11. Effect of previous vaccination with pneumococcal conjugate vaccine on pneumococcal polysaccharide vaccine antibody responses.
Schaballie H; Wuyts G; Dillaerts D; Frans G; Moens L; Proesmans M; Vermeulen F; De Boeck K; Meyts I; Bossuyt X
Clin Exp Immunol; 2016 Aug; 185(2):180-9. PubMed ID: 26939935
[TBL] [Abstract][Full Text] [Related]
12. Imputing the Direct and Indirect Effectiveness of Childhood Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease by Surveying Temporal Changes in Nasopharyngeal Pneumococcal Colonization.
Nzenze SA; Madhi SA; Shiri T; Klugman KP; de Gouveia L; Moore DP; Karstaedt AS; Tempia S; Nunes MC; von Gottberg A
Am J Epidemiol; 2017 Aug; 186(4):435-444. PubMed ID: 28482004
[TBL] [Abstract][Full Text] [Related]
13. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway.
Vestrheim DF; Løvoll O; Aaberge IS; Caugant DA; Høiby EA; Bakke H; Bergsaker MR
Vaccine; 2008 Jun; 26(26):3277-81. PubMed ID: 18456376
[TBL] [Abstract][Full Text] [Related]
15. The direct effect of pneumococcal conjugate vaccines on invasive pneumococcal disease in children in the Latin American and Caribbean region (SIREVA 2006-17): a multicentre, retrospective observational study.
Agudelo CI; Castañeda-Orjuela C; Brandileone MCC; Echániz-Aviles G; Almeida SCG; Carnalla-Barajas MN; Regueira M; Fossati S; Alarcón P; Araya P; Duarte C; Sánchez J; Novas M; Toraño-Peraza G; Rodríguez-Ortega M; Chamorro-Cortesi G; Kawabata A; García-Gabarrot G; Camou T; Spadola E; Payares D; Andrade AL; Di Fabio JL; Castañeda E;
Lancet Infect Dis; 2021 Mar; 21(3):405-417. PubMed ID: 32986996
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of a 7-valent pneumococcal conjugate vaccine (PCV7) and impact on carriage in Venezuelan children at risk of invasive pneumococcal diseases.
Rivera-Olivero IA; Del Nogal B; Fuentes M; Cortez R; Bogaert D; Hermans PW; Waard JH
Vaccine; 2014 Jun; 32(31):4006-11. PubMed ID: 24837505
[TBL] [Abstract][Full Text] [Related]
17. The Antibody Response Following a Booster With Either a 10- or 13-valent Pneumococcal Conjugate Vaccine in Toddlers Primed With a 13-valent Pneumococcal Conjugate Vaccine in Early Infancy.
Trück J; Jawad S; Goldblatt D; Roalfe L; Snape MD; Voysey M; Pollard AJ
Pediatr Infect Dis J; 2016 Jul; 35(7):787-93. PubMed ID: 27088583
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Korea.
Sohn HS; Suh DC; Jang E; Kwon JW
J Manag Care Pharm; 2010; 16(1):32-45. PubMed ID: 20044845
[TBL] [Abstract][Full Text] [Related]
19. Pneumococcal serotype-specific antibodies persist through early childhood after infant immunization: follow-up from a randomized controlled trial.
Trück J; Snape MD; Tatangeli F; Voysey M; Yu LM; Faust SN; Heath PT; Finn A; Pollard AJ
PLoS One; 2014; 9(3):e91413. PubMed ID: 24618837
[TBL] [Abstract][Full Text] [Related]
20. Humoral response to conjugate pneumococcal vaccine in paediatric oncology patients.
Cheng FW; Ip M; Chu YY; Lin Z; Lee V; Shing MK; Leung WK; Yuen PM; Li CK
Arch Dis Child; 2012 Apr; 97(4):358-60. PubMed ID: 21109505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
